Invest in a translational science platform with regional advantage.
Antimicrobial resistance is one of the defining health challenges of the century. CABI-SEA offers a de-risked, IP-backed pathway into a growing market — anchored in Southeast Asian biodiversity.
Why partner with CABI-SEA
Defensible IP
A patent portfolio spanning composition, formulation, and application.
Institutional backing
Anchored at Prince of Songkla University with sustained public funding.
Market pull
Global demand for AMR alternatives and natural-ingredient antimicrobials.
Regional access
Direct access to ASEAN biodiversity, clinical networks, and manufacturing.
How we partner
Licensing
License a patented technology or formulation for your market and channel.
Co-development
Joint R&D on a specific product, disease area, or industry application.
Sponsored research
Fund targeted programmes with milestone-based deliverables.
Distribution
Take proven prototypes into your regional or international channels.
Request the CABI-SEA investor one-pager.
A concise brief covering our platform, IP position, market opportunity, and current partnership needs.